DZD2269 / Dizal Pharma - LARVOL DELTA

Clinical pharmacokinetic/pharmacodynamic relationship of DZD2269, a potent and selective A2aR antagonist designed to overcome high levels of adenosine induced immunosuppression. (ASCO 2022) - P1 | "Single oral dose of DZD2269 ranging from 5 mg to 160 mg was safe and well tolerated. Good PK/PD correlation was demonstrated in the study. DZD2269 could effectively reverse high adenosine induced immunosuppression."

Clinical • IO biomarker • PK/PD data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist. (PubMed, J Exp Clin Cancer Res) - P1 | "DZD2269 is a novel A2aR antagonist which can fully block A2aR mediated immunosuppression commonly found in TME. Clinical development of DZD2269 in patients with cancer is warranted (NCT04634344)."

IO biomarker • Journal • Immune Modulation • Inflammation • Oncology

Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC (clinicaltrials.gov) - P1 | N=16 | Terminated | Sponsor: Dizal Pharmaceuticals | N=57 ➔ 16 | Recruiting ➔ Terminated; Due to reasons of internal business strategy, not related to study or site conduct.

Enrollment change • Trial termination • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Study of DZD2269 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=72 | Completed | Sponsor: Dizal Pharmaceuticals | Recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Apr 2022 | Trial primary completion date: Nov 2022 ➔ Apr 2022

Trial completion • Trial completion date • Trial primary completion date • Solid Tumor

Dizal to Demonstrate the Strength and Rapid Acceleration of its Clinical Portfolio at ASCO 2022 (PRNewswire) - "Dizal will present clinical results and updates from its four therapeutic candidates in solid tumors and hematologic malignancies at the 2022 Annual Meeting of the American Society of Cancer Oncology (ASCO) being held on June 3-7, 2022. New data from Dizal's investigational cancer medicines demonstrate the rapid progression of its oncology pipeline."

EGFR exon 20 • P1 data • P1/2 data • Breast Cancer • Hematological Malignancies • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma

A Study of DZD2269 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=68 | Recruiting | Sponsor: Dizal Pharmaceuticals | Trial completion date: Dec 2021 ➔ Dec 2022 | Trial primary completion date: Dec 2021 ➔ Nov 2022

Trial completion date • Trial primary completion date

A Study of DZD2269 in Healthy Adult Participants (clinicaltrials.gov) - P1; N=68; Recruiting; Sponsor: Dizal Pharmaceuticals; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • PCR

A Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Effect of Food on Pharmacokinetics of DZD2269 Oral Tablet in Healthy Adult Participants (clinicaltrials.gov) - P1; N=68; Not yet recruiting; Sponsor: Dizal Pharmaceuticals

New P1 trial

Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC (clinicaltrials.gov) - P1; N=57; Recruiting; Sponsor: Dizal Pharmaceuticals; Not yet recruiting ➔ Recruiting; Initiation date: Nov 2020 ➔ Apr 2021

Clinical • Enrollment open • Trial initiation date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC (clinicaltrials.gov) - P1; N=57; Not yet recruiting; Sponsor: Dizal Pharmaceuticals

Clinical • New P1 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor